Develop and own proprietary C-Bond nanotechnology for glass strengthening. Produce and sell C-Bond NanoShield for enhancing automotive windshield safety and performance. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 43% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $643K. In times of high interest rates, a gap like that can squeeze a company.
The market pays 0.2× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 76% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 43% a year on average.
Over the last 12 months, company executives reported 9 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.0005. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.